CTC
ADMA icon

Central Trust Company’s ADMA Biologics ADMA Stock Holding History

Central Trust Company’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15
Closed -$136 – 1572
2026
Q1 		$136 Hold
15
– – ﹤0.01% 1552
2025
Q4 		$274 Buy
+15
New +$253 ﹤0.01% 1489

Other funds holding ADMA

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
RL
Ruffer LLP London, United Kingdom $2.83B AUM 30.34% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Central Trust Company's ADMA Position: Q2 2026 in Review

Central Trust Company sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 15 shares — an estimated $136 sold.

Central Trust Company first reported a position in ADMA in Q4 2025 and held it in 2 quarters. The position peaked at $274 in Q4 2025. 86 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Central Trust Company reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Central Trust Company sold 15 ADMA Biologics shares in Q2 2026, an estimated $136.
  • Central Trust Company first reported a position in ADMA Biologics in Q4 2025 and held it in 2 quarters.
  • Central Trust Company's ADMA Biologics position peaked at $274 in Q4 2025.
  • 86 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.